We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$4.88B
AUM Growth
+$975M
Cap. Flow
+$671M
Cap. Flow %
13.75%
Top 10 Hldgs %
41.91%
Holding
108
New
15
Increased
25
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
SYY icon
Sysco
SYY
+$82.5M
2
LEGN icon
Legend Biotech
LEGN
+$79.9M
3
BHVN icon
Biohaven
BHVN
+$57.8M
4
NOW icon
ServiceNow
NOW
+$47.9M
5
QURE icon
uniQure
QURE
+$47M

Top Sells

Rank Stock Value
1
ETNB
89bio
ETNB
+$122M
2
KDP icon
Keurig Dr Pepper
KDP
+$40.1M
3
FERG icon
Ferguson
FERG
+$35.1M
4
RNAM
Avidity Biosciences
RNAM
+$32.7M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 51.05%
2 Technology 10.74%
3 Consumer Discretionary 6.34%
4 Financials 4.61%
5 Consumer Staples 3.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMG icon
51
Chipotle Mexican Grill
CMG
$41.5B
$25.4M 0.52%
+686,300
New +$24.8M
AURA icon
52
Aura Biosciences
AURA
$826M
$23.8M 0.49%
4,372,884
– –
TNGX icon
53
Tango Therapeutics
TNGX
$4.41B
$23.6M 0.48%
+2,662,227
New +$22.9M
BIIB icon
54
Biogen
BIIB
$30.7B
$23.3M 0.48%
132,290
-35,900
-21% -$5.87M
DKS icon
55
Dick's Sporting Goods
DKS
$18.7B
$22.6M 0.46%
114,300
-13,990
-11% -$3.05M
GS icon
56
Goldman Sachs
GS
$303B
$21.2M 0.43%
24,108
– –
JNJ icon
57
Johnson & Johnson
JNJ
$625B
$20.4M 0.42%
98,786
-34,000
-26% -$6.72M
INSM icon
58
Insmed
INSM
$28.6B
$19M 0.39%
109,313
-108,470
-50% -$19.8M
ABEO icon
59
Abeona Therapeutics
ABEO
$413M
$14.1M 0.29%
2,676,000
– –
LXEO icon
60
Lexeo Therapeutics
LXEO
$378M
$12.4M 0.25%
+1,250,000
New +$11.4M
RCKT icon
61
Rocket Pharmaceuticals
RCKT
$394M
$10.5M 0.22%
2,992,735
-850,598
-22% -$2.91M
MOLN
62
Molecular Partners
MOLN
$9.68M 0.2%
2,221,494
– –
EXAS
63
DELISTED
Exact Sciences
EXAS
$9.56M 0.2%
94,100
– –
WHWK
64
Whitehawk Therapeutics
WHWK
$271M
$8.95M 0.18%
3,700,000
– –
IFRX icon
65
InflaRx
IFRX
$271M
$8.01M 0.16%
7,933,910
+1,450,000
+22% +$1.8M
TMO icon
66
Thermo Fisher Scientific
TMO
$220B
$7.76M 0.16%
13,400
– –
ABT icon
67
Abbott
ABT
$187B
$6.39M 0.13%
51,020
– –
MRNA icon
68
Moderna
MRNA
$23.6B
$6.06M 0.12%
+205,593
New +$5.59M
KZR
69
DELISTED
Kezar Life Sciences
KZR
$4.51M 0.09%
716,759
– –
COR icon
70
Cencora
COR
$61.2B
$4.22M 0.09%
12,488
– –
UTHR icon
71
United Therapeutics
UTHR
$23.1B
$3.65M 0.07%
7,500
– –
ISRG icon
72
Intuitive Surgical
ISRG
$134B
$2.95M 0.06%
5,200
– –
MTD icon
73
Mettler-Toledo International
MTD
$28.6B
$2.74M 0.06%
1,964
– –
MDT icon
74
Medtronic
MDT
$112B
$2.41M 0.05%
25,060
– –
NTRA icon
75
Natera
NTRA
$46.4B
$2.31M 0.05%
10,100
– –
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Suvretta Capital Management held 108 positions worth $4.88B, up 25% from $3.91B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Suvretta Capital Management deployed $671M of net new capital in Q4 2025, opening 15 new positions and adding to 25 existing holdings. Its largest new stake was Sysco: 1,083,790 shares worth $79.9M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 51% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Ferguson, an estimated $35.1M trimmed.

  • Suvretta Capital Management's largest Q4 2025 buy was Sysco: 1,083,790 shares worth $79.9M.
  • Suvretta Capital Management added most to Legend Biotech in Q4 2025, an estimated $79.9M increase.
  • Suvretta Capital Management's biggest Q4 2025 reduction was Ferguson, cutting an estimated $35.1M.
  • Suvretta Capital Management fully exited 89bio in Q4 2025, selling an estimated $122M.
  • Suvretta Capital Management's ten largest holdings make up 42% of its $4.88B portfolio in Q4 2025.
  • Suvretta Capital Management opened 15 new positions and closed 15 in Q4 2025.
  • Suvretta Capital Management's portfolio value rose 25% quarter-over-quarter to $4.88B.

Based on Suvretta Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.